AnaptysBio, Inc. ANAB Biopharma Company — Noncash Advance Future Royalties Interest Expense

Other segment segments

Similar metrics at other companies

BBIONoncash interest expense on deferred royalty obligations

$39.87M+66.0%

ARWRNon-cash interest expense on liability related to the sale of future royalties

$8.83M+60.6%

BCRXNon-cash interest expense on royalty financing obligations

$13.29M-1.6%

RARENon Cash Interest Expense On Liability Related To Sale Of Future Royalties

$21M+50.0%

BBIONoncash interest expense on deferred royalty obligations

$39.87M+66.0%

NKTRNon Cash Interest Expense Related To Sale Of Royalties

$7.94M+59.7%

Questions, answered.

What is AnaptysBio, Inc.'s biopharma company — noncash advance future royalties interest expense?

AnaptysBio, Inc. (ANAB) reported biopharma company — noncash advance future royalties interest expense of $0 in Q1 2026.

What does biopharma company — noncash advance future royalties interest expense mean?

This metric tracks the non-cash interest expense associated with financing arrangements involving future royalty streams. It highlights the cost of capital for non-dilutive funding structures used to support clinical development. Investors use this to understand the impact of complex financing agreements on the company's long-term financial obligations.